Ipsen’s Iqirvo normalizes ALP in 85.3% of patients in Phase III PBC trial

• Ipsen reported Phase III ELSPIRE results showing Iqirvo normalized a liver disease marker more often than placebo in primary biliary cholangitis.
• The trial covered patients with mildly elevated marker levels, supporting potential use in a broader patient population.
• Iqirvo was generally well tolerated, with no new safety signals; expanded patient data are being shared with regulators.
• Results will be presented at The Liver Meeting 2026 and simultaneously published in Hepatology.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ipsen SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611051130PRIMZONEFULLFEED1001302077) on November 05, 2026, and is solely responsible for the information contained therein.